Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Non-specific Effects of FLU-MMR Vaccines in Adults (FLUMMR-BRA)

27 maj 2022 uppdaterad av: Radboud University Medical Center

Study of the Non-specific Effects of Influenza and MMR Vaccine on Infectious Diseases in Goiânia, Goiás, Brazil

Various observational studies have reported an association between influenza vaccination and lower rates of infection with SARS-Cov-2 and less COVID-19 disease severity have been reported in large epidemiological studies in US, Brazil and Italy. Observational studies from the Netherlands showed also strongly reduced COVID-19 infection rates among influenza-vaccinated healthcare workers, with ORs of 0.61 and 0.49 for the first and second wave of COVID-19, respectively. In addition, in-vitro immunological analyses showed that the quadrivalent inactivated influenza vaccine can induce a trained immunity program against SARS-CoV-2 (2). In-vivo vaccination against influenza was also shown to induce improved interferon responses against SARS-CoV-2, with modulation of hyperinflammatory responses. Trained immunity could be the underlying mechanism for the potential protective effect of influenza vaccine, a mechanism that has also been proven for BCG vaccination, and epidemiological evidence suggests similar non-specific effects of MMR and OPV vaccination. Currently, various clinical trials are being conducted to study the impact of BCG, MMR and OPV vaccination on COVID-19, but prospective clinical data on influenza vaccination are lacking. Although specific COVID-19 vaccines have been developed and are proven effective, there are important reasons for assessing in a controlled randomized trial the effect of influenza and MMR vaccine on COVID19:

  • Specific COVID-19 vaccines are still not yet available for all segments of the population, and especially not for the majority of the population in developing countries.
  • The emergence of new SARS-CoV-2 variants, especially the P1 variant from Brazil, may very well be associated with reduced response to vaccines. An immunomodulatory protective vaccine that protects in an antigen-independent manner would be of great importance.
  • It would also be conceptually important to know whether influenza and the MMR vaccine can induce heterologous protection against another viral infection, in the context of future pandemics.

Studieöversikt

Status

Rekrytering

Betingelser

Intervention / Behandling

Studietyp

Interventionell

Inskrivning (Förväntat)

2000

Fas

  • Tidig fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

  • Brasilien
    • Goiás
      • Goiânia, Goiás, Brasilien
        • Rekrytering
        • Faculdade da Polícia Militar
        • Kontakt:
        • Kontakt:
          • Sérgio Nascente, PhD
          • Telefonnummer: +556284179227
        • Huvudutredare:
          • Clayson Moura Gomes, PhD

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

To be eligible to participate in this study, the participant must meet the following criteria:

• Be older than 18 years old. Observation: the elderly is at risk for severe forms of COVID-19, therefore, the evidence in this age group is very relevant. However, they can also be a first priority population to receive a specific vaccine, limiting the time to follow-up on the study. In addition, influenza and MMR vaccines can lead to a lower immune system in the elderly than in young people. Therefore, it is likely that a more rational choice will be to carry out the study in a young population.

Exclusion Criteria:

Participants will not be included in the study if they present (reported by the research participants):

  • Known allergy to components of influenza and MMR vaccines or serious adverse events to previous administration.
  • Fever (> 38 degrees Celsius) in the last 24 hours.
  • Pregnancy. Note: pregnancy should be avoided for one month after vaccination.
  • Symptoms of active viral or bacterial infection.
  • Documented diagnosis of COVID-19.
  • Vaccination in the last 4 weeks against SARS-CoV-2.
  • Immunocompromised participants. This exclusion category includes: a) infection with the human immunodeficiency virus (HIV-1); b) neutropenic participant with less than 500 neutrophils/mm3; c) participant with organ transplantation; d) participants with bone marrow transplantation; e) participants in chemotherapy treatment; f) participants with primary immunodeficiency; g) participants with severe lymphopenia with less than 400 lymphocytes/mm3; h) treatment with any anti-cytokine medication; i) treatment with oral or intravenous steroids, for example, daily doses of prednisone or equivalent for more than 3 months, or probable use of oral or intravenous steroids within next four weeks.
  • Some type of lymphoma or malignancy in the previous two years.
  • Direct involvement in the design or execution of the study.
  • Absence from work for more than 4 weeks within the next 12 weeks after study admission (vacation, maternity leave, retirement, planned surgery, etc.)

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Förebyggande
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Enda

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Placebo-jämförare: Placebo
sterile 0.9% NaCl
Övrig: Placebo
Placebo: 0.5 ml of 0.9% NaCl will be administered intradermally in the left upper arm.
Experimentell: Influenza
Influenza (tetravalent vaccine)
Biologisk: Influenza
Influenza: 0.5 ml of reconstituted Influenza vaccine will be administered intramuscularly in the left upper arm as recommended by the manufacturer.
Experimentell: MMR
measles, mumps, and rubella vaccine
Biologisk: MMR vaccines
MMR: 0.5 ml of reconstituted MMR vaccine will be administered intramuscularly in the left upper arm as recommended by the manufacturer.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Cumulative incidence of SARS-CoV-2 infection during 1 year follow up
Tidsram: 3 months after inclusion

COVID-19 will be defined as meeting the following two criteria:

  1. signs and symptoms compatible with the disease as judged by the adjudication committee based on the most recent knowledge of COVID-19
  2. microbiological or radiological confirmation: meeting any of the following: a. presence of SARS-CoV-2 virus by PCR
3 months after inclusion
Cumulative incidence of SARS-CoV-2 infection
Tidsram: 6 months after inclusion

COVID-19 will be defined as meeting the following two criteria:

  1. signs and symptoms compatible with the disease as judged by the adjudication committee based on the most recent knowledge of COVID-19
  2. microbiological or radiological confirmation: meeting any of the following: a. presence of SARS-CoV-2 virus by PCR
6 months after inclusion
Cumulative incidence of SARS-CoV-2 infection
Tidsram: 12 months after inclusion

COVID-19 will be defined as meeting the following two criteria:

  1. signs and symptoms compatible with the disease as judged by the adjudication committee based on the most recent knowledge of COVID-19
  2. microbiological or radiological confirmation: meeting any of the following: a. presence of SARS-CoV-2 virus by PCR
12 months after inclusion

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Severity of SARS-CoV-2 and the incidence of clinically relevant RTI
Tidsram: 3, 6 and 12 months after inclusion
Cumulative incidence of hospitalization for COVID-19; Cumulative incidence of ICU admission for COVID-19; Cumulative incidence of death due to COVID-19; All parameters combined, measured as number of days or number of deaths will be used to report COVID19 severity.
3, 6 and 12 months after inclusion
Severity of other respiratory tract infections (RTIs)
Tidsram: 3, 6 and 12 months after inclusion

Cumulative incidence of hospitalization for other RTIs; Cumulative incidence of hospitalization for all infections; Cumulative incidence of death due to other infections;

All parameters combined, measured as number of days or number of deaths will be used to report the severity of the infection.

Cumulative incidence of hospitalization for all infections
3, 6 and 12 months after inclusion
Incidence and magnitude of plasma/serum antibodies (IgA, M, G) and SARS-Cov-2-specific antibodies at the end of study
Tidsram: 3, 6 and 12 months after inclusion
The measurement of the antibodies titers will be used together with the self informed questionnaires in order to confirm the incidence of COVID19 and/or other RTIs.
3, 6 and 12 months after inclusion

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Radboud University Medical Center

Samarbetspartners

Faculdade da Polícia Militar, Goiânia, GO - Brazil

Utredare

  • Huvudutredare: Mihai Netea, PhD, Radboud University Medical Center

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

1 maj 2021

Primärt slutförande (Förväntat)

1 januari 2023

Avslutad studie (Förväntat)

1 mars 2023

Studieregistreringsdatum

Först inskickad

19 maj 2022

Först inskickad som uppfyllde QC-kriterierna

27 maj 2022

Första postat (Faktisk)

2 juni 2022

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

2 juni 2022

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

27 maj 2022

Senast verifierad

1 maj 2022

Mer information

Termer relaterade till denna studie

Nyckelord

Andra studie-ID-nummer

  • FLUMMR-BRA

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Kliniska prövningar på Covid-19

Kliniska prövningar på Placebo

Sök liknande försök

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

CROs by country

CROs in Montenegro

Betingelser

Sällsynta sjukdomar

Läkemedelsinterventioner

Kosttillskott

Sponsor / medarbetare

Platser

3
Prenumerera